Why Is Coinbase Stock Going Down?
Every way you look at it, Coinbase has had a…
Sell
18
KRYS Quote, Financials, Valuation and Earnings
Last price:
$159.62
Seasonality move
:
6.28%
Day range:
$158.25 - $161.93
52-week range:
$107.50 - $219.34
Dividend yield:
0%
P/E ratio:
89.49x
P/S ratio:
19.40x
P/B ratio:
5.17x
Volume:
233.5K
Avg. volume:
277.7K
1-year change:
24.16%
Market cap:
$4.6B
Revenue:
$50.7M
EPS (TTM):
$1.78
Analysts' Opinion
-
Consensus RatingKrystal Biotech has received a consensus rating of Buy. The company's average rating is a Buy based on 8 Buy ratings, 1 Hold rating, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $207.78, Krystal Biotech has an estimated upside of 30.44% from its current price of $159.29.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $195.00 representing 100% downside risk from its current price of $159.29.
Fair Value
-
According to the consensus of 9 analysts, Krystal Biotech has 30.44% upside to fair value with a price target of $207.78 per share.
KRYS vs. S&P 500
-
Over the past 5 trading days, Krystal Biotech has underperformed the S&P 500 by -1.62% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
Krystal Biotech does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Krystal Biotech has grown year-over-year revenues for 0 quarters straight. In the most recent quarter Krystal Biotech reported revenues of $83.8M.
Earnings Growth
-
Krystal Biotech has grown year-over-year earnings for 0 quarters straight. In the most recent quarter Krystal Biotech reported earnings per share of $0.91.
Enterprise value:
4B
EV / Invested capital:
4.51x
Price / LTM sales:
19.40x
EV / EBIT:
22.81x
EV / Revenue:
16.53x
PEG ratio (5yr expected):
--
EV / Free cash flow:
68.77x
Price / Operating cash flow:
80.72x
Enterprise value / EBITDA:
22.05x
Gross Profit (TTM):
$223.5M
Return On Assets:
6%
Net Income Margin (TTM):
21.69%
Return On Equity:
6.45%
Return On Invested Capital:
6.45%
Operating Margin:
41.67%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2023-09-30 | 2024-09-30 | |
| Income Statement | ||||||
| Revenue | -- | -- | $241.5M | $8.6M | $83.8M | |
| Gross Profit | -- | $8.3M | $223.5M | $8.3M | $77.2M | |
| Operating Income | -$107.3M | -$135.1M | $65M | -$26M | $34.9M | |
| EBITDA | -$104.3M | -$150.8M | $181.1M | -$24.6M | $36.5M | |
| Diluted EPS | -$5.21 | -$1.47 | $1.78 | $2.79 | $0.91 | |
| Period Ending | 2020-09-30 | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $287.7M | $345.8M | $397.6M | $582.1M | $713.2M | |
| Total Assets | $311.5M | $451.1M | $576.4M | $790.4M | $982.3M | |
| Current Liabilities | $7.2M | $35.8M | $28M | $27.6M | $89.5M | |
| Total Liabilities | $9.7M | $42.9M | $35.6M | $34.4M | $96.5M | |
| Total Equity | $301.7M | $408.2M | $540.8M | $755.9M | $885.8M | |
| Total Debt | -- | -- | -- | -- | -- | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2023-09-30 | 2024-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$99.1M | -$103.9M | $63.3M | -$21.2M | $58.9M | |
| Cash From Investing | -$235.4M | $87.6M | -$89.8M | $105.2M | -$34.3M | |
| Cash From Financing | $234.4M | $203.2M | $27.2M | $13.4M | $3.4M | |
| Free Cash Flow | -$187.8M | -$119.1M | $58.1M | -$23M | $57.8M | |
KRYS
Sector
Market Cap
$4.6B
$45.9M
Price % of 52-Week High
72.62%
46.95%
Dividend Yield
0%
0%
Shareholder Yield
--
-0.6%
1-Year Price Total Return
24.16%
-32.15%
Beta (5-Year)
0.799
0.772
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Technicals
8-day SMA
Sell
Level
$161.30
200-day SMA
Sell
Level
$179.22
Bollinger Bands (100)
Sell
Level
171.53 - 193.23
Chaikin Money Flow
Sell
Level
-22.9K
20-day SMA
Sell
Level
$174.16
Relative Strength Index (RSI14)
Sell
Level
37.79
ADX Line
Sell
Level
15.41
Williams %R
Buy
Level
-89.1058
50-day SMA
Sell
Level
$178.32
MACD (12, 26)
Sell
Level
-6.68
25-day Aroon Oscillator
Sell
Level
-56
On Balance Volume
Neutral
Level
29.8M
Financial Scores
Buy
Altman Z-Score
(Annual)
Level (53.39)
--
CA Score
(Annual)
Level (--)
--
Beneish M-Score
(Annual)
Level (--)
Buy
Momentum Score
Level (9)
--
Ohlson Score
Level (--)
--
Piotroski F Score
(Annual)
Level (--)
Sell
Quality Ratio Score
Level (4)
Buy
Fundamental Score
Level (5)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Krystal Biotech Inc is engaged in the healthcare sector in the United States. It is focused on the development of easy-to-use, redosable gene therapies to improve the lives of patients living with debilitating diseases. The company used its proprietary gene therapy platform, STAR-D to develop treatments for rare or orphan dermatological indications caused by the absence of or a mutation in a single gene. It plans to leverage its platform to expand its pipeline to include other dermatological indications in the future. The company has one operating segment, which is the business of developing and commercializing pharmaceutical products.
Stock Forecast FAQ
In the current month, KRYS has received 8 Buy ratings 1 Hold ratings, and 0 Sell ratings. The KRYS average analyst price target in the past 3 months is $207.78.
-
Where Will Krystal Biotech Stock Be In 1 Year?
According to analysts, the consensus estimate is that Krystal Biotech share price will rise to $207.78 per share over the next 12 months.
-
What Do Analysts Say About Krystal Biotech?
Analysts are divided on their view about Krystal Biotech share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Krystal Biotech is a Sell and believe this share price will drop from its current level to $195.00.
-
What Is Krystal Biotech's Price Target?
The price target for Krystal Biotech over the next 1-year time period is forecast to be $207.78 according to 9 Wall Street analysts, 8 of them rate the stock a Buy, 0 rate the stock a Sell, and 1 analyst rates the stock a Hold.
-
Is KRYS A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Krystal Biotech is a Buy. 8 of 9 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of KRYS?
You can purchase shares of Krystal Biotech via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, TastyTrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Krystal Biotech shares.
-
What Is The Krystal Biotech Share Price Today?
Krystal Biotech was last trading at $159.62 per share. This represents the most recent stock quote for Krystal Biotech. Yesterday, Krystal Biotech closed at $159.29 per share.
-
How To Buy Krystal Biotech Stock Online?
In order to purchase Krystal Biotech stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is Uber Stock a Buy on the Dip?
Shares of Uber Technologies (NYSE:UBER) have been fading fast in…
Is AMD Stock an All-Time Buy?
Advanced Micro Devices (NASDAQ:AMD) is a high-growth AI stock that…
Stock Ideas
Buy
64
Is AAPL Stock a Buy?
Market Cap: $3.9T
P/E Ratio: 42x
Buy
52
Is NVDA Stock a Buy?
Market Cap: $3.4T
P/E Ratio: 115x
Buy
54
Is MSFT Stock a Buy?
Market Cap: $3.2T
P/E Ratio: 36x
Alerts
Sell
50
LMND alert for Dec 28
Lemonade [LMND] is down 10.69% over the past day.
Sell
50
TSLL alert for Dec 28
Direxion Daily TSLA Bull 2X Shares [TSLL] is down 9.92% over the past day.
Buy
63
SMLR alert for Dec 28
Semler Scientific [SMLR] is down 9.65% over the past day.
